RITUXIMAB Safety Questions, RITUXIMAB Answers


More Here>>Side Effects - FDA Reports 2006-2008

Medications A-Z:   A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Welcome! Patientsville.com provides unique information about RITUXIMAB. Our extensive database of RITUXIMAB adverse events and RITUXIMAB warnings is updated regularly. If you have questions, you can post them to one of our health experts or ask others in our broad patient community.

>> Announcements
Check out our Hospital and Home Care Quality Reports.

Ask Our Health Experts about RITUXIMAB

Do You Have a Question about Your Health?

Our Doctors and Nurses will Help You Understand Your Symptoms and Feel Better!
Private, Confidential and Discreet




RITUXIMAB Safety Reports

Total RITUXIMAB reports: 398.
RITUXIMAB FDA safety alerts: 2004 2006 .
Reported deaths: 76    Reported hospitalizations: 240.
Take RITUXIMAB Side Effects Survey or Share Your RITUXIMAB Story. Read More Here.

Showing 1-75 of 398 Next >

Physician from UNITED KINGDOM reported RITUXIMAB problem on May 10, 2007. Female patient, weighting 98.77 lb, was diagnosed with b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: septic shock. RITUXIMAB dosage: 600 MG, Q28D. During the same period patient was treated with FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, INSULIN RETARD LEO, FLUKONAZOL. Patient died on 05/01/2007.

RITUXIMAB problem was reported by a Physician from UNITED KINGDOM on May 10, 2007. Female patient was diagnosed with non-hodgkin's lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: oesophageal candidiasis. RITUXIMAB dosage: 600 MG, Q28D. During the same period patient was treated with CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, INSULIN RETARD LEO, SEPTRA, PAROXETINE, FORTASEC. Patient was hospitalized. Patient recovered.

Physician from ITALY reported RITUXIMAB problem on May 04, 2007. Female patient, weighting 127.9 lb, was diagnosed with b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: overdose. RITUXIMAB dosage: 375 MG, UNK. Patient recovered.

RITUXIMAB problem was reported by a Physician from GERMANY on May 08, 2007. Female patient, weighting 165.3 lb, was diagnosed with rheumatoid arthritis, osteoporosis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: anaemia, multi-organ failure, pleural effusion, pneumonia, staphylococcal sepsis. RITUXIMAB dosage: 1000 MG, SINGLE. During the same period patient was treated with INFLIXIMAB, METHOTREXATE, MELYSDON, TERIPARATIDE, CALCIUM D, MOBLOC, RAMIPRIL. Patient was hospitalized. Patient died on 04/21/2007.

Health Professional from FRANCE reported RITUXIMAB problem on May 11, 2007. Male patient was diagnosed with b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: cerebral haematoma, paranoia, status epilepticus. RITUXIMAB dosage: 575 MG/M2, UNK. During the same period patient was treated with CORTANCYL, ENDOXAN, FARMARUBICINE, ELDISINE, METHOTREXATE, RIMIFON. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Physician from UNITED KINGDOM on May 11, 2007. Female patient, weighting 149.9 lb, was diagnosed with rheumatoid arthritis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: cough, cryptogenic organising pneumonia. RITUXIMAB dosage: 1000 MG, QD. During the same period patient was treated with FOSAMAX, CORTANCYL, METHOTREXATE, SPECIAFOLDINE. Patient recovered.

Physician from GERMANY reported RITUXIMAB problem on May 11, 2007. Female patient, weighting 143.3 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: condition aggravated. RITUXIMAB dosage: 660 MG, SINGLE. During the same period patient was treated with BENDAMUSTINE. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Physician from UNITED STATES on May 10, 2007. Male patient, 29 years of age, was diagnosed with non-hodgkin's lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: leukoencephalopathy. RITUXIMAB dosage: 10 MG, 1/WEEK, WK 1. During the same period patient was treated with GLUCOCORTICOIDS, ACETAMINOPHEN, DIPHENHYDRAMINE. Patient recovered.

Consumer or non-health professional from UNITED STATES reported RITUXIMAB problem on May 23, 2007. Female patient was diagnosed with b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: cerebrovascular accident. RITUXIMAB dosage: unknown. During the same period patient was treated with CISPLATIN, CYTARABINE, DEXAMETHASONE. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Pharmacist from UNITED STATES on May 21, 2007. Male patient, weighting 218.0 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: back pain, hypotension, pruritus, syncope, tachycardia. RITUXIMAB dosage: 935 MG ONCE IV. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RITUXIMAB problem on May 17, 2007. Female patient, weighting 99.21 lb, was diagnosed with systemic lupus erythematosus, gastritis, osteoporosis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: myelitis transverse. RITUXIMAB dosage: 1000 MG, 1/WEEK. During the same period patient was treated with ACETAMINOPHEN, POLARAMINE, SAXIZON, NIZATIDINE, CALCIUM CHLORIDE. Patient recovered.

RITUXIMAB problem was reported by a Consumer or non-health professional from UNITED STATES on May 23, 2007. Female patient, weighting 114.2 lb, was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: asthenia, atelectasis, breath sounds abnormal, confusional state, delirium, pyrexia, respiratory distress, wheezing. RITUXIMAB dosage: 1156 MG. Patient recovered.

Physician from UNITED STATES reported RITUXIMAB problem on May 18, 2007. Female patient, weighting 160.3 lb, was diagnosed with rheumatoid arthritis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: chest discomfort. RITUXIMAB dosage: 1000 MG, UNK. During the same period patient was treated with PREDNISONE, PLAVIX, CRESTOR, SINGULAIR, ASPIRIN, SEREVENT, COMBIVENT. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Consumer or non-health professional from UNITED STATES on May 15, 2007. Female patient, 20 years of age, was diagnosed with lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: cerebral haemorrhage. RITUXIMAB dosage: unknown. During the same period patient was treated with CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PREDNISONE. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RITUXIMAB problem on May 17, 2007. Female patient was diagnosed with systemic lupus erythematosus and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: pulmonary embolism. RITUXIMAB dosage: 1000 MG/BODY 2 TIMES. Patient died on 03/24/2007.

RITUXIMAB problem was reported by a Health Professional from UNITED STATES on Jan 08, 2007. Female patient, weighting 205.0 lb, was diagnosed with rheumatoid arthritis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: refusal of treatment by patient, rheumatoid arthritis. RITUXIMAB dosage: 1000 MG, X2. During the same period patient was treated with ACETAMINOPHEN, IBUPROFEN, FOLIC ACID, METHOTREXATE, ALESSE, SLOW FE, NAPROXEN. Patient recovered.

Physician from JAPAN reported RITUXIMAB problem on May 17, 2007. Female patient was diagnosed with systemic lupus erythematosus and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: systemic lupus erythematosus. RITUXIMAB dosage: 1000 MG/BODY. During the same period patient was treated with IMMUNOSUPPRESSANT NOS. Patient recovered.

RITUXIMAB problem was reported by a Physician from UNITED KINGDOM on May 24, 2007. Male patient was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: cardiac failure congestive, coronary artery disease, pneumonia cytomegaloviral. RITUXIMAB dosage: 375 MG/M2, X4. During the same period patient was treated with CYCLOPHOSPHAMIDE, PREDNISOLONE, DILTIAZEM, ISOSORBIDE MONONITRATE, PERINDOPRIL ERBUMINE. Patient was hospitalized. Patient died on 12/26/2006.

Physician from JAPAN reported RITUXIMAB problem on May 17, 2007. Female patient, weighting 99.21 lb, was diagnosed with systemic lupus erythematosus, gastritis, osteoporosis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: myelitis transverse. RITUXIMAB dosage: 1000 MG, 1/WEEK. During the same period patient was treated with ACETAMINOPHEN, POLARAMINE, SAXIZON, NIZATIDINE, CALCIUM CHLORIDE. Patient recovered.

RITUXIMAB problem was reported by a Consumer or non-health professional from UNITED KINGDOM on May 23, 2007. Female patient, weighting 154.3 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: neuropathy. RITUXIMAB dosage: 375 MG/M2, UNK. During the same period patient was treated with FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, COTRIMOXAZOLE, VALACYCLOVIR. Patient was hospitalized. Patient recovered.

Physician from UNITED KINGDOM reported RITUXIMAB problem on May 22, 2007. Female patient, weighting 198.4 lb, was diagnosed with non-hodgkin's lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: febrile neutropenia, septic shock. RITUXIMAB dosage: unknown. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Consumer or non-health professional from UNITED STATES on May 29, 2007. Female patient, 69 years of age, was diagnosed with diffuse large b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: blood pressure decreased, intestinal perforation, white blood cell count decreased. RITUXIMAB dosage: 825MG. During the same period patient was treated with CYCLOPHOSPHAMIDE, PREDNISONE, VINCRISTINE, ASPIRIN, GLUCOSAMINE, CALCIUM CHLORIDE, TOLTERODINE, ENALAPRIL MALEATE. Patient recovered.

Physician from JAPAN reported RITUXIMAB problem on May 25, 2007. Male patient, weighting 152.1 lb, was diagnosed with non-hodgkin's lymphoma, anaemia, hepatic cirrhosis, prophylaxis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: gastrointestinal haemorrhage, tumour lysis syndrome. RITUXIMAB dosage: 375 MG, QD. During the same period patient was treated with FERROMIA, LASIX, ALDACTONE, URSO, OCTOTIAMINE, ASPARA, CHINESE MEDICINE, MOSAPRIDE CITRATE. Patient recovered.

RITUXIMAB problem was reported by a Consumer or non-health professional from FRANCE on May 29, 2007. Male patient, weighting 140.0 lb, was diagnosed with b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: febrile neutropenia, leukopenia, sinusitis. RITUXIMAB dosage: unknown. During the same period patient was treated with CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, PARACETAMOL, CETIRIZINE, VINCRISTINE. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RITUXIMAB problem on May 24, 2007. Male patient was diagnosed with systemic lupus erythematosus and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: hypogammaglobulinaemia. RITUXIMAB dosage: 200 MG, QD. During the same period patient was treated with CELLCEPT, AZATHIOPRINE, ENDOXAN, DIAMOX, PREDNISOLONE, BAKTAR. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Consumer or non-health professional from UNITED STATES on May 22, 2007. Female patient, weighting 264.6 lb, was diagnosed with systemic lupus erythematosus and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: lupus nephritis. RITUXIMAB dosage: unknown. During the same period patient was treated with PREDNISONE, CELLCEPT, IMURAN. Patient recovered.

Physician from GERMANY reported RITUXIMAB problem on May 23, 2007. Female patient, weighting 165.3 lb, was diagnosed with rheumatoid arthritis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: disseminated tuberculosis. RITUXIMAB dosage: 1000 MG, UNK. During the same period patient was treated with HUMIRA, ARAVA. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Physician from NEW ZEALAND on May 23, 2007. Male patient was diagnosed with b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, hepatic steatosis, transaminases increased. RITUXIMAB dosage: 750 MG, UNK. During the same period patient was treated with CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISONE. Patient recovered.

Physician from UNITED KINGDOM reported RITUXIMAB problem on May 25, 2007. Male patient was diagnosed with non-hodgkin's lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: febrile neutropenia. RITUXIMAB dosage: 730 MG, UNK. During the same period patient was treated with CISPLATIN, DEXAMETHASONE, NEUPOGEN. Patient was hospitalized. Patient died on 05/04/2007.

RITUXIMAB problem was reported by a Physician from JAPAN on May 25, 2007. Male patient, weighting 123.5 lb, was diagnosed with non-hodgkin's lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: gastric cancer. RITUXIMAB dosage: 375 MG, UNK. During the same period patient was treated with FLUDARABINE PHOSPHATE, BIOFERMIN, CYANOCOBALAMIN, RILMAZAFONE HYDROCHLORIDE, AMLODIPINE BESYLATE, SENNA LEAF, SUCRALFATE, ETIZOLAM. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from UNITED STATES reported RITUXIMAB problem on May 25, 2007. Female patient, child 4 years of age, was diagnosed with opsoclonus myoclonus and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: neuroblastoma. RITUXIMAB dosage: 375 MG/M2, 1/WEEK. During the same period patient was treated with IMMUNE GLOBULIN INTRAVENOUS, CORTICOTROPIN. Patient recovered.

RITUXIMAB problem was reported by a Physician from GERMANY on May 23, 2007. Female patient, weighting 125.7 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with RITUXIMAB. RITUXIMAB dosage: 375 MG, Q4W. During the same period patient was treated with BENDAMUSTINE, ASPIRIN, ENALAPRIL MALEATE, SIMVASTATIN, CARBAMAZEPINE, TORSEMIDE, DAFALGAN, CLEXANE. Patient died on 12/21/2006.

Physician from GERMANY reported RITUXIMAB problem on May 30, 2007. Female patient, weighting 149.9 lb, was diagnosed with rheumatoid arthritis, osteoporosis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: deafness. RITUXIMAB dosage: 1000 MG, UNK. During the same period patient was treated with METHOTREXATE, ARCOXIA, CALCIMAGON. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Consumer or non-health professional from FRANCE on May 31, 2007. Female patient was diagnosed with burkitt's lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: acute coronary syndrome, cardiac failure. RITUXIMAB dosage: 375 MG/M2, QD. During the same period patient was treated with CYCLOPHOSPHAMIDE, VINCRISTINE, DOXORUBICIN. Patient died on 05/28/2007.

Health Professional from UNITED STATES reported RITUXIMAB problem on June 05, 2007. Male patient, weighting 180.6 lb, was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: acute myeloid leukaemia, adverse event, myelodysplastic syndrome, no therapeutic response. RITUXIMAB dosage: 375 MG/M2 Q 6 MONTHS X 4 IV. Patient died on 05/18/2007.

RITUXIMAB problem was reported by a Pharmacist from UNITED STATES on June 07, 2007. Female patient, 51 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: chills, dyspnoea, infusion related reaction, no therapeutic response, oxygen saturation decreased, wheezing. RITUXIMAB dosage: 375MG/M2 ONCE IV DRIP. Patient was hospitalized. Patient recovered.

Physician from UNITED KINGDOM reported RITUXIMAB problem on May 28, 2007. Male patient, weighting 181.9 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with RITUXIMAB. RITUXIMAB dosage: UNK MG/M2, UNK. During the same period patient was treated with FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE. Patient died on 04/20/2007.

RITUXIMAB problem was reported by a Consumer or non-health professional from UNITED STATES on June 08, 2007. Female patient, 84 years of age, was diagnosed with b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: bone marrow failure. RITUXIMAB dosage: 375 MG/M2, UNK. During the same period patient was treated with FLUDARABINE PHOSPHATE, PANTOPRAZOLE, AMLODIPINE, CLONAZEPAM, ACYCLOVIR. Patient recovered.

Physician from ITALY reported RITUXIMAB problem on June 01, 2007. Male patient, weighting 196.2 lb, was diagnosed with non-hodgkin's lymphoma and was treated with RITUXIMAB. RITUXIMAB dosage: 770 MG, Q2M. During the same period patient was treated with WARFARIN, ALLOPURINOL. Patient died on 05/17/2007.

RITUXIMAB problem was reported by a Physician from UNITED STATES on June 04, 2007. Female patient, weighting 188.7 lb, was diagnosed with rheumatoid arthritis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: infusion related reaction. RITUXIMAB dosage: 1000 MG, DAYS 1+15. During the same period patient was treated with TETANUS TOXOID, PNEUMOCOCCAL POLYSACCHARIDE VACCINE, KEYHOLE LIMPET HEMOCYANIN, CANDIDA ALBICANS SKIN TEST. Patient recovered.

Physician from UNITED KINGDOM reported RITUXIMAB problem on June 01, 2007. Male patient was diagnosed with anti-neutrophil cytoplasmic antibody positive vasculitis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: embolic stroke. RITUXIMAB dosage: 375 MG/M2, X3. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Physician from UNITED KINGDOM on June 04, 2007. Male patient, 67 years of age, weighting 165.3 lb, was diagnosed with mantle cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: febrile neutropenia, thrombocytopenia. RITUXIMAB dosage: 700 MG, UNK. During the same period patient was treated with CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, VINCRISTINE. Patient recovered.

Physician from ITALY reported RITUXIMAB problem on June 12, 2007. Male patient, weighting 196.2 lb, was diagnosed with non-hodgkin's lymphoma and was treated with RITUXIMAB. RITUXIMAB dosage: 770 MG, Q2M. During the same period patient was treated with WARFARIN, ALLOPURINOL. Patient died on 05/17/2007.

RITUXIMAB problem was reported by a Physician from UNITED KINGDOM on June 08, 2007. Female patient, weighting 198.4 lb, was diagnosed with non-hodgkin's lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: febrile neutropenia, septic shock. RITUXIMAB dosage: 750 MG, UNK. Patient was hospitalized. Patient recovered.

Pharmacist from UNITED STATES reported RITUXIMAB problem on June 12, 2007. Female patient, weighting 145.5 lb, was diagnosed with b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: abdominal pain upper, chills, infusion related reaction. RITUXIMAB dosage: 630 MG IV. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Consumer or non-health professional from UNITED STATES on June 08, 2007. Male patient, 80 years of age, was diagnosed with waldenstrom's macroglobulinaemia and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: cryoglobulinaemia, renal failure. RITUXIMAB dosage: 375 MG/M2, 1/WEEK. Patient recovered.

Physician from UNITED KINGDOM reported RITUXIMAB problem on June 04, 2007. Female patient, weighting 114.6 lb, was diagnosed with rheumatoid arthritis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: lymphadenopathy. RITUXIMAB dosage: 1000 MG, UNK. During the same period patient was treated with METHOTREXATE, PREDNISOLONE. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Physician from UNITED KINGDOM on June 08, 2007. Female patient, weighting 149.9 lb, was diagnosed with rheumatoid arthritis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: cryptogenic organising pneumonia. RITUXIMAB dosage: 1000 MG, QD. During the same period patient was treated with FOSAMAX, CORTANCYL, METHOTREXATE, SPECIAFOLDINE. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RITUXIMAB problem on June 12, 2007. Male patient, 65 years of age, weighting 122.4 lb, was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii stage ii and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: abdominal distension, anorexia, gastric cancer, gastritis erosive, lymphocyte count decreased, stomach discomfort. RITUXIMAB dosage: 375 MG/M2, 1X/DAY. During the same period patient was treated with FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Physician from UNITED STATES on June 11, 2007. Female patient, 79 years of age, was diagnosed with waldenstrom's macroglobulinaemia and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: mononeuropathy multiplex. RITUXIMAB dosage: 375 MG/M2, UNK. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from UNITED KINGDOM reported RITUXIMAB problem on June 12, 2007. Female patient, weighting 20.06 lb, was diagnosed with b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: febrile neutropenia. RITUXIMAB dosage: 375 MG/M2, UNK. During the same period patient was treated with CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, FILGRASTIM, ACYCLOVIR, COTRIMOXAZOLE, OMEPRAZOLE. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Physician from AUSTRALIA on June 08, 2007. Male patient, 55 years of age, was diagnosed with vasculitis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: chest pain. RITUXIMAB dosage: unknown. During the same period patient was treated with CYCLOPHOSPHAMIDE. Patient was hospitalized. Patient recovered.

Physician from UNITED KINGDOM reported RITUXIMAB problem on June 08, 2007. Male patient was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: pneumonia cytomegaloviral. RITUXIMAB dosage: 375 MG/M2, X4. During the same period patient was treated with CYCLOPHOSPHAMIDE, PREDNISOLONE, DILTIAZEM, ISOSORBIDE MONONITRATE, PERINDOPRIL ERBUMINE. Patient was hospitalized. Patient died on 12/26/2006.

RITUXIMAB problem was reported by a Physician from UNITED KINGDOM on June 08, 2007. Female patient, weighting 125.2 lb, was diagnosed with vasculitis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: pneumonia, pulmonary embolism. RITUXIMAB dosage: 562 MG, 1/WEEK. During the same period patient was treated with CYCLOPHOSPHAMIDE, METHYLPREDNISOLONE, ADCAL, AMPHOTERICIN B LOZENGES, DIGOXIN, FUROSEMIDE, LANSOPRAZOLE. Patient was hospitalized. Patient recovered.

Physician from FINLAND reported RITUXIMAB problem on June 07, 2007. Male patient, weighting 149.9 lb, was diagnosed with b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: urinary retention. RITUXIMAB dosage: 690 MG, UNK. During the same period patient was treated with PREDNISONE, VINCRISTINE, DOXORUBICIN, CYCLOPHOSPHAMIDE, PARACETAMOL, CETIRIZINE. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Physician from FRANCE on June 13, 2007. Male patient, weighting 189.6 lb, was diagnosed with b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: febrile neutropenia. RITUXIMAB dosage: 750 MG, Q3W. During the same period patient was treated with CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE. Patient was hospitalized. Patient recovered.

Physician from SPAIN reported RITUXIMAB problem on June 14, 2007. Male patient, weighting 165.3 lb, was diagnosed with b-cell lymphoma, prophylaxis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: hepatitis. RITUXIMAB dosage: 652 MG, QD. During the same period patient was treated with PARACETAMOL, SEPTRA, OMEPRAZOLE. Patient recovered.

RITUXIMAB problem was reported by a Physician from GERMANY on June 11, 2007. Female patient, weighting 165.3 lb, was diagnosed with rheumatoid arthritis, osteoporosis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: anaemia, multi-organ failure, pleural effusion, pneumonia, staphylococcal sepsis. RITUXIMAB dosage: 1000 MG, SINGLE. During the same period patient was treated with INFLIXIMAB, METHOTREXATE, TERIPARATIDE, CALCIUM D, FOLCUR, METYSOLON, FORTEO. Patient was hospitalized. Patient died on 04/21/2007.

Consumer or non-health professional from UNITED KINGDOM reported RITUXIMAB problem on June 15, 2007. Female patient, weighting 150.0 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: delirium, pneumocystis jiroveci infection, pneumonia. RITUXIMAB dosage: 890 MG, X3. During the same period patient was treated with FLUDARABINE, CYCLOPHOSPHAMIDE, PANTOPRAZOLE, ASPIRIN, MOCLOBEMIDE, PROVERA, TEMAZEPAM. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Consumer or non-health professional from BELGIUM on June 11, 2007. Male patient was diagnosed with rheumatoid arthritis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: gastrointestinal disorder. RITUXIMAB dosage: 1000 MG, DAYS 1+15. During the same period patient was treated with METHYLPREDNISOLONE, PREDNISONE, METHOTREXATE, FOLIC ACID, DAFALGAN CODEINE, IDOMETHINE. Patient was hospitalized. Patient recovered.

Physician from SPAIN reported RITUXIMAB problem on June 11, 2007. Female patient, 48 years of age, was diagnosed with systemic lupus erythematosus and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: neutropenia, pyrexia, white blood cell count decreased. RITUXIMAB dosage: 375 MG/M2, UNK. Patient recovered.

RITUXIMAB problem was reported by a Physician from UNITED STATES on June 12, 2007. Male patient, weighting 196.0 lb, was diagnosed with multiple sclerosis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: cholecystitis acute. RITUXIMAB dosage: unknown. Patient was hospitalized. Patient recovered.

Physician from FRANCE reported RITUXIMAB problem on June 14, 2007. Female patient, weighting 185.2 lb, was diagnosed with b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: pulmonary tuberculosis. RITUXIMAB dosage: unknown. During the same period patient was treated with CYCLOPHOSPHAMIDE, MITOXANTRONE, FLUDARABINE PHOSPHATE. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Consumer or non-health professional from UNITED STATES on June 15, 2007. Female patient, weighting 172.8 lb, was diagnosed with rheumatoid arthritis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: thrombocytopenia. RITUXIMAB dosage: 1000 MG, UNK. Patient was hospitalized. Patient recovered.

Physician from FRANCE reported RITUXIMAB problem on June 14, 2007. Female patient, weighting 185.2 lb, was diagnosed with b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: pulmonary tuberculosis. RITUXIMAB dosage: unknown. During the same period patient was treated with CYCLOPHOSPHAMIDE, MITOXANTRONE, FLUDARABINE PHOSPHATE. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Consumer or non-health professional from UNITED KINGDOM on June 15, 2007. Female patient, weighting 154.3 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: neuropathy. RITUXIMAB dosage: 375 MG/M2, UNK. During the same period patient was treated with FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, COTRIM, VALACYCLOVIR. Patient was hospitalized. Patient recovered.

Physician from UNITED KINGDOM reported RITUXIMAB problem on June 04, 2007. Female patient, weighting 114.6 lb, was diagnosed with rheumatoid arthritis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: lymphadenopathy. RITUXIMAB dosage: 1000 MG, UNK. During the same period patient was treated with METHOTREXATE, PREDNISOLONE. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Physician from UNITED STATES on June 19, 2007. Female patient, weighting 188.7 lb, was diagnosed with rheumatoid arthritis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: infusion related reaction. RITUXIMAB dosage: 1000 MG, DAYS 1+15. During the same period patient was treated with TETANUS TOXOID, PNEUMOCOCCAL POLYSACCHARIDE VACCINE, KEYHOLE LIMPET HEMOCYANIN, CANDIDA ALBICANS SKIN TEST. Patient recovered.

Physician from GERMANY reported RITUXIMAB problem on June 07, 2007. Female patient, weighting 165.3 lb, was diagnosed with rheumatoid arthritis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: disseminated tuberculosis. RITUXIMAB dosage: 1000 MG, UNK. During the same period patient was treated with HUMIRA, ARAVA, STEROIDS NOS, TAVEGIL. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Physician from UNITED STATES on June 20, 2007. Female patient was diagnosed with rheumatoid arthritis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: breast cancer. RITUXIMAB dosage: 1000 MG, DAYS 1+15. During the same period patient was treated with METHYLPREDNISOLONE, PREDNISONE, FOLIC ACID, INSULIN, MONOPRIL, ROSIGLITAZONE, METHOTREXATE, HYDROXYCHLOROQUINE SULPHATE. Patient was hospitalized. Patient recovered.

Physician from FRANCE reported RITUXIMAB problem on June 13, 2007. Male patient, weighting 189.6 lb, was diagnosed with b-cell lymphoma and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: febrile neutropenia. RITUXIMAB dosage: 750 MG, Q3W. During the same period patient was treated with CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE. Patient was hospitalized. Patient recovered.

RITUXIMAB problem was reported by a Physician from JAPAN on June 22, 2007. Male patient, 65 years of age, weighting 122.4 lb, was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii stage ii and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: gastric cancer. RITUXIMAB dosage: 375 MG/M2, 1X/DAY. During the same period patient was treated with FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE. Patient was hospitalized. Patient recovered.

Physician from GERMANY reported RITUXIMAB problem on June 22, 2007. Female patient was diagnosed with chronic lymphocytic leukaemia and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: epstein-barr virus infection. RITUXIMAB dosage: 50 MG/M2, UNK. During the same period patient was treated with FLUDARA, CAMPATH, BENADRYL, ACETAMINOPHEN, COTRIM. Patient died on 01/01/2007.

RITUXIMAB problem was reported by a Physician from SPAIN on June 25, 2007. Male patient, weighting 165.3 lb, was diagnosed with b-cell lymphoma, prophylaxis and was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: hepatitis b. RITUXIMAB dosage: 652 MG, QD. During the same period patient was treated with ACETAMINOPHEN, SEPTRA, OMEPRAZOLE. Patient recovered.

Pharmacist from UNITED STATES reported RITUXIMAB problem on June 21, 2007. Female patient was treated with RITUXIMAB. After drug was administered, patient experienced the following problems/side effects: acute myeloid leukaemia, myelodysplastic syndrome. RITUXIMAB dosage: 375 MG/M2, 1/WEEK. During the same period patient was treated with ACETAMINOPHEN, DIPHENHYDRAMINE, HYDROCORTISONE. Patient recovered.

Showing 1-75 of 398 Next >

Ask Our Patient Community about RITUXIMAB

Select a Medication and Click to Access Reports about Side Effects and Adverse Reactions

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

This drug has as active FDA Safety Alert This drug has an active FDA Safety Alert
A
Abacavir sulfate
Abatacept
Abilify
Acamprosate calcium
AccuprilThis drug has as active FDA Safety Alert
AccutaneThis drug has as active FDA Safety Alert
AceonThis drug has as active FDA Safety Alert
Aciphex
Actiq (fentanyl citrate)
ActimmuneThis drug has as active FDA Safety Alert
(aripiprazole) (quinapril) (isotretinoin) (perindopril) (rabeprazole) (interferon gamma-1b)
ActonelThis drug has as active FDA Safety Alert (risedronate)
Actoplus MetThis drug has as active FDA Safety Alert (pioglitazone)
ActosThis drug has as active FDA Safety Alert (pioglitazone)
AcuTect (technetium Tc 99m apcitide)
Adefovir dipivoxil
Advair Diskus(Fluticasone propionate; Salmeterol xinafoate)
AdderallThis drug has as active FDA Safety Alert (amphetamine salts)
Agenerase (amprenavir)
Aggrastat (tirofiban)
Alamast (pemirolast)
AlendronateThis drug has as active FDA Safety Alert
AlemtuzumabThis drug has as active FDA Safety Alert
AleveThis drug has as active FDA Safety Alert (naproxen sodium)
Alfuzosin
Alinia (nitazoxanide)
Alimta (pemetrexed)
Alitretinoin
Almotriptan malateThis drug has as active FDA Safety Alert
Alosetron hydrochloride
Aloxi (palonosetron)
Alrex (loteprednol etabonate)
AltaceThis drug has as active FDA Safety Alert (ramipril)
Ambien (zolpidem tartrate)
AmergeThis drug has as active FDA Safety Alert (naratriptan)
Aminolevulinic acid
AmiodaroneThis drug has as active FDA Safety Alert
Amitiza (lubiprostone)
AmnesteemThis drug has as active FDA Safety Alert (isotretinoin)
Amphadase (hyaluronidase)
luronidase)
Amphetamine saltsThis drug has as active FDA Safety Alert
Amprenavir
AnaproxThis drug has as active FDA Safety Alert (naproxen sodium)
Angiomax (bivalirudin)
Anidulafungin
Antagon (ganirelix acetate)
Anthelios SX (avobenzone, ecamsule, octocrylene)
Apidra (insulin glulisine recombinant)
Apokyn (apomorphine)
Aprepitant
Aprotinin
Aptivus (tipranavir)
AranespThis drug has as active FDA Safety Alert (darbepoetin alpha)
Arava (leflunomide)
Arformoterol

Argatroban
ArediaThis drug has as active FDA Safety Alert (pamidronate)
Aripiprazole
Arixtra (fondaparinux)
Aromasin (exemestane)
Arranon (nelarabine)
Arsenic trioxide
Aspirin
Atacand (candesartan cilexetil)
Atazanavir sulfate
AtomoxetineThis drug has as active FDA Safety Alert
Avastin (bevacizumab)
Avelox (moxifloxacin)
Avobenzone, Ecamsule, Octocrylene
Avodart (dutasteride)
Avonex (interferon beta-1a)
AxertThis drug has as active FDA Safety Alert (almotriptan malate)
Azacitidine
Azilect (rasagiline)
Azopt (brinzolamide)

back to top

B
Balsalazide disodium
Baraclude (entecavir)
BenazeprilThis drug has as active FDA Safety Alert
Benicar (olmesartan medoxomil)
Bevacizumab
Bexarotene
BextraThis drug has as active FDA Safety Alert (valdecoxib)
BiaxinThis drug has as active FDA Safety Alert (clarithromycin)
Bimatoprost
Bivalirudin
BonivaThis drug has as active FDA Safety Alert (ibandronate)
Bortezomib
Brinzolamide
Brovana (arformoterol)
BupropionThis drug has as active FDA Safety Alert
Butisol sodium
Byetta (exenatide)


back to top

C
Calfactant
CampathThis drug has as active FDA Safety Alert (alemtuzumab)
Campral (acamprosate calcium)
Cancidas (caspofungin)
Candesartan cilexetil
Capecitabine
CapotenThis drug has as active FDA Safety Alert (captopril)
CaptoprilThis drug has as active FDA Safety Alert
CarbamazepineThis drug has as active FDA Safety Alert
CarbatrolThis drug has as active FDA Safety Alert (carbamazepine)
Carbrital (pentobarbital and carbromal)
Caspofungin
Cefditoren pivoxil
CefepimeThis drug has as active FDA Safety Alert
CeftriaxoneThis drug has as active FDA Safety Alert
CelebrexThis drug has as active FDA Safety Alert (celecoxib)
CelecoxibThis drug has as active FDA Safety Alert
CelexaThis drug has as active FDA Safety Alert (citalopram hydrobromide)
Cetrorelix acetate
Cetrotide (cetrorelix acetate)
Cetuximab
Cevimeline
ChantixThis drug has as active FDA Safety Alert (varenicline)
Cialis (tadalafil)
Cilostazol
Cinacalcet
Cirlesonide
CitalopramThis drug has as active FDA Safety Alert
ClaravisThis drug has as active FDA Safety Alert (isotretinoin)
ClarithromycinThis drug has as active FDA Safety Alert
Clarinex (desloratadine)
Clolar (clofarabine)
Clofarabine
Clozapine
Clozaril (clozapine)
CodeineThis drug has as active FDA Safety Alert
Colazal (balsalazide disodium)
Colesevelam
ColistimethateThis drug has as active FDA Safety Alert
Coly-Mycin M (colistimethate)This drug has as active FDA Safety Alert
Comtan (entacapone)
Concerta (methylphenidate)
Conivaptan
CordaroneThis drug has as active FDA Safety Alert (amiodarone)
CrestorThis drug has as active FDA Safety Alert (rosuvastatin calcium)
Cubicin (daptomycin)
Curosurf (poractant alfa)
CylertThis drug has as active FDA Safety Alert (pemoline)
CymbaltaThis drug has as active FDA Safety Alert (duloxetine)
CytotecThis drug has as active FDA Safety Alert (misoprostol)

back to top

D
Dacogen (decitabine)
Dalfopristin
Dalmane (flurazepam)
Daptomycin
Darbepoetin alphaThis drug has as active FDA Safety Alert
Darifenacin
Darunavir
Dasatinib
Daytrana (methylphenidate transdermal)
DDAVPThis drug has as active FDA Safety Alert (desmopressin)
DDAVP Nasal SprayThis drug has as active FDA Safety Alert (demopressin)
DDAVP Rhinal TubeThis drug has as active FDA Safety Alert (desmopressin)
DDVPThis drug has as active FDA Safety Alert (desmopressin
Decitabine
Deferasirox
Definity (perflutren lipid microspheres)
DepaconThis drug has as active FDA Safety Alert (valproate)
DepakeneThis drug has as active FDA Safety Alert (valproate)
DepakoteThis drug has as active FDA Safety Alert (valproate)
Desloratadine
DesmopressinThis drug has as active FDA Safety Alert
Detrol (tolterodine tartrate)
terodine tartrate)
Dexedrine (dextroamphetamine sulfate)
Dexmedetomidine
Dexmethylphenidate HCl
> Dextroamphetamine sulfate
Diastat AcuDialThis drug has as active FDA Safety Alert
Diazepam rectal gelThis drug has as active FDA Safety Alert
DidronelThis drug has as active FDA Safety Alert (etidronate)
DiprivanThis drug has as active FDA Safety Alert (propofol)
Dofetilide
Doral (quazepam)
Doxercalcif
Drospirenone
DuloxetineThis drug has as active FDA Safety Alert
DuragesicThis drug has as active FDA Safety Alert (fentanyl transdermal system)
Dutasteride

back to top

E

Eculizumab
Edetate disodium
Efalizumab
Efavirenz
EffexorThis drug has as active FDA Safety Alert (venlafaxine)
Elestat (epinastine)
EletriptanThis drug has as active FDA Safety Alert
Elidel (pimecrolimus)
Ellence (epirubicin)
Eloxatin (oxaliplatin)
Emend (aprepitant)
Emtricitabine
Emtriva (emtricitabine)
Enablex (darifenacin)
Enalapril / EnalaprilatThis drug has as active FDA Safety Alert
Endrate (edetate disodium)
Enfuvirtide
Entacapone
Entecavir
Epinastine
Epirubicin
Eplerenone
Epoetin alfaThis drug has as active FDA Safety Alert
EpogenThis drug has as active FDA Safety Alert (epoetin alfa)
Eptifibatide
EquetroThis drug has as active FDA Safety Alert (carbamazepine)
Eraxis (anidulafungin)
Erbitux (cetuximab)
Ertaczo (sertaconazole)
EscitalopramThis drug has as active FDA Safety Alert
Estazolam
Eszopiclone
Ethchlorvynol

Ethinyl estradiol
EtidronateThis drug has as active FDA Safety Alert
Evoxac (cevimeline)
Exelon (rivastigmine tartrate)
Exenatide
Exjade (deferasirox)
Exemestane
Extraneal (icodextrin)
Ezetimibe
Ezetimibe/simvastatin

back to top

F
Factive (gemifloxacin mesylate)
Faslodex (fulvestrant)
FelbamateThis drug has as active FDA Safety Alert
FelbatolThis drug has as active FDA Safety Alert (felbamate)
Fentanyl buccal tabletsThis drug has as active FDA Safety Alert
Fentanyl citrate
Fentanyl transdermal systemThis drug has as active FDA Safety Alert
FentoraThis drug has as active FDA Safety Alert (fentanyl buccal tablets)
Ferrlecit (sodium ferric gluconate complex)
Fleet Accu-PrepThis drug has as active FDA Safety Alert (sodium phosphate)
Fleet Phospho-SodaThis drug has as active FDA Safety Alert (sodium phosphate)
FluoxetineThis drug has as active FDA Safety Alert
Flurazepam
Fluticasone propionate
FluvoxamineThis drug has as active FDA Safety Alert
Focalin (dexmethylphenidate)
Focalin XR (dexmethylphenidate)
Fomivirsen
Fondaparinux
Foradil (formoterol fumarate)
Formoterol fumarate
FosamaxThis drug has as active FDA Safety Alert (alendronate)
FosinoprilThis drug has as active FDA Safety Alert
FrovaThis drug has as active FDA Safety Alert (frovatriptan succinate)
Frovatriptan succinateThis drug has as active FDA Safety Alert
Fulvestrant
Fuzeon (enfuvirtide)

G
GabapentinThis drug has as active FDA Safety Alert
GabitrilThis drug has as active FDA Safety Alert (tiagabine)
Gadobenate DimeglumineThis drug has as active FDA Safety Alert
GadodiamideThis drug has as active FDA Safety Alert
GadoliniumThis drug has as active FDA Safety Alert
Gadopentetate DimeglumineThis drug has as active FDA Safety Alert
GadoteridolThis drug has as active FDA Safety Alert
GadoversetamideThis drug has as active FDA Safety Alert
GalantamineThis drug has as active FDA Safety Alert
Ganirelix acetate
GatifloxacinThis drug has as active FDA Safety Alert
GefitinibThis drug has as active FDA Safety Alert
Gemifloxacin mesylate
Gemtuzumab ozogamicin
Geodon (ziprasidone)
Gleevec (imatinib mesylate)

back to top

H
Halcion (triazolam)
HaldolThis drug has as active FDA Safety Alert (haloperidol)
Haloperidol
This drug has as active FDA Safety Alert
Hectorol (doxercalcif)
Hepsera (adefovir dipivoxil)
Hyaluronidase
Hydase (hyaluronidase)
Human Secretin

back to top

I
IbandronateThis drug has as active FDA Safety Alert
Ibuprofen
Icodextrin
Iloprost
Imatinib mesylate
Increlex (Mecasermin [rDNA origin]
Infasurf Preservative Free (calfactant)
ImitrexThis drug has as active FDA Safety Alert (sumatriptan)
Innohep (tinzaparin)
Inspra (eplerenone)
Insulin Aspart recombinant
Insulin Detemir recombinant
Insulin Glargine recombinant

Insulin Glulisine recombinant

Intron A (interferon alfa-2b)
Integrilin (eptifibatide)
ifibatide)
Interferon alfa-2b
Interferon beta-1a
Interferon gamma-1bThis drug has as active FDA Safety Alert
Invega (paliperidone)
Iplex  (mecasermin rinfabate)
IressaThis drug has as active FDA Safety Alert (gefitinib)
IsotretinoinThis drug has as active FDA Safety Alert

back to top

J
Januvia (sitagliptin phosphate)

back to top

K
Kaletra (lopinavir; ritonavir)
Kepivance (palifermin)
KeppraThis drug has as active FDA Safety Alert (levetiracetam)
Ketek (telithromycin)
Ketotifen fumarate

back to top

L
LamictalThis drug has as active FDA Safety Alert (lamotrigine)
LamotrigineThis drug has as active FDA Safety Alert
Lantus (insulin glargine recombinant)
Leflunomide
Lenalidomide
Lepirudin recombinant
Levalbuterol
Levemir (insulin detemir recombinant)
LevetiracetamThis drug has as active FDA Safety Alert
Levitra (vardenafil)
Levonorgestrel
Levothyroxine sodium
Levulan Kerastick (aminolevulinic acid)
LexaproThis drug has as active FDA Safety Alert (escitalopram)
Lindane
Linezolid
This drug has as active FDA Safety Alert
LisinoprilThis drug has as active FDA Safety Alert
Lopinavir/ritonavir
Lotemax (loteprednol etabonate)
LotensinThis drug has as active FDA Safety Alert (benazepril)
Loteprednol etabonate
Lotronex (alosetron hydrochloride)
Lubiprostone
Lucentis (ranibizumab)
Lumigan (bimatoprost)
Lunestra (eszopiclone)
LyricaThis drug has as active FDA Safety Alert (pregabalin)

back to top

M
Macugen (pegaptanib)
MagnevistThis drug has as active FDA Safety Alert (gadopentetate dimeglumine)
Maraviroc
MavikThis drug has as active FDA Safety Alert (trandolapril)
MaxaltThis drug has as active FDA Safety Alert (rizatriptan benzoate)
MaxipimeThis drug has as active FDA Safety Alert (cefepime)
Mecasermin [rDNA origin]
Mecasermin-rinfabate
Meloxicam
Memantine
Metadate CD (methylphenidate HCl)
ylphenidate HCl)
Methylphenidate HCl
Methylphenidate transdermal
Mequinol
Micafungin
Micardis (telmisartan)
misartan)
MifeprexThis drug has as active FDA Safety Alert (mifepristone)
MifepristoneThis drug has as active FDA Safety Alert
Miglustat
MinirinThis drug has as active FDA Safety Alert (desmopressin)
MirtazapineThis drug has as active FDA Safety Alert
MisoprostolThis drug has as active FDA Safety Alert
Mobic (meloxicam)
Modafinil
MoexiprilThis drug has as active FDA Safety Alert
MonoprilThis drug has as active FDA Safety Alert (fosinopril)
Moxifloxacin
MultiHanceThis drug has as active FDA Safety Alert (gadobenate dimeglumine)
Mycamine (micafungin)
Mylotarg (gemtuzumab ozogamicin)

back to top

N
Namenda (memantine)
NaprosynThis drug has as active FDA Safety Alert (naproxen)
NaproxenThis drug has as active FDA Safety Alert
Naratriptan
Nesiritide recombinant
Nateglinide
Natrecor (nesiritide recombinant)
NefazodoneThis drug has as active FDA Safety Alert
Nelarabine
NeoTect Kit (technetium Tc 99m depreotide)
Nesiritide recombinant
NeurontinThis drug has as active FDA Safety Alert (gabapentin)
Nexavar (sorafenib)
Nitazoxanide
Nitisinone
Norelgestromin
NovoLog (insulin aspart recombinant)
Noxafil (posaconazole)

back to top